Finally, significantly lower increments of IL-6 were observed in LIST 2 compared to LIST 1 only in the BC group when we compared the iAUCs (Fig. 6) and the percent changes from baseline 2h after LIST [LIST 1: 351% (243–601%); LIST 2: 254% (178–339%), p = 0.028]. This evidence concerns the gene IL6 and breast cancer.